Invitrogen™ ADAR Polyclonal Antibody

Catalog No.	Quantity
PIPA596839	100 μL

Catalog No. PIPA596839 Supplier Invitrogen™ Supplier No. PA596839

Description

Rabbit Polyclonal Antibody

Positive Samples: U-87MG, A549, DU145, HeLa, HepG2; Cellular Location: Cytoplasm, Nucleus, Nucleus, nucleolus.

Adenosine Deaminase RNA Specific (ADAR) catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing.This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. ADAR can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. (Uniprot).

Specifications

• Antigen: ADAR
• Applications: ELISA, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry
• Classification: Polyclonal
• Concentration: 0.46 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with 50% glycerol and 0.05% ProClin 300; pH 7.3
• Gene: Adar
• Gene Accession No.: P55265, P55266, Q99MU3
• Gene Alias: 136 kDa double-stranded RNA-binding protein; ADA; Adar; ADAR1; Adar1p110; Adar1p150; Adenosine Deaminase; adenosine deaminase acting on RNA 1-A; adenosine deaminase RNA specific; adenosine deaminase, RNA specific; adenosine deaminase, RNA-specific; AGS6; AV242451; double-stranded RNA-specific adenosine deaminase; DRADA; DSH; DSRAD; dsRNA adenosine deaminase; dsRNA adeonosine deaminase; G1P1; IFI4; IFI-4; interferon-induced protein 4; interferon-inducible protein 4; K88DSRBP; LOW QUALITY PROTEIN: double-stranded RNA-specific adenosine deaminase; mZaADAR; P136; RNA adenosine deaminase 1; RNA-specific adenosine deaminase p110 form; RNA-specific adenosine deaminase p150 form
• Gene Symbols: Adar
• Host Species: Rabbit
• Immunogen: Synthetic peptide.
• Purification Method: Affinity Chromatography
• Quantity: 100 μL
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 103, 56417, 81635
• Target Species: Human, Mouse, Rat
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov